Literature DB >> 22329185

In-transit melanoma: an individualized approach.

Travis E Grotz1, Aaron S Mansfield, Lisa A Kottschade, Lori A Erickson, Clark C Otley, Svetomir N Markovic, James W Jakub.   

Abstract

The majority of locoregional recurrences in melanoma occur in the form of intradermal or subcutaneous local or in-transit metastasis. In-transit melanoma represents contamination of the lymphatic space that, if treated, can result in long-term cure in a subset of patients. The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior. A number of different treatment options exist, but there is no level 1 evidence to guide clinical decision-making. Herein we present our institutional treatment algorithm, which allows for individualization based on the patient's presentation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22329185

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  11 in total

Review 1.  Current treatment of locoregional recurrence of melanoma.

Authors:  Malcolm Hart Squires; Keith A Delman
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 2.  Subcutaneous metastases from melanoma: a discussion of clinical experience.

Authors:  Piotr Rutkowski; Marcin Zdzienicki; Katarzyna Kozak
Journal:  Melanoma Manag       Date:  2014-09-05

3.  Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins.

Authors:  Alexandra B Gonzalez; Christian L Baum; Jerry D Brewer; Christopher J Arpey; William S Harmsen; Vera J Suman; Svetomir N Markovic; James W Jakub
Journal:  J Surg Oncol       Date:  2018-08-16       Impact factor: 3.454

4.  Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma.

Authors:  Laura Chin-Lenn; Claire Temple-Oberle; J Gregory McKinnon
Journal:  Plast Surg (Oakv)       Date:  2015       Impact factor: 0.947

5.  Tumor deposits in rectal adenocarcinoma after neoadjuvant chemoradiation are associated with poor prognosis.

Authors:  Purva Gopal; Pengcheng Lu; Gregory D Ayers; Alan J Herline; Mary K Washington
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

Review 6.  Melanoma immunotherapy.

Authors:  Martina Sanlorenzo; Igor Vujic; Christian Posch; Akshay Dajee; Adam Yen; Sarasa Kim; Michelle Ashworth; Michael D Rosenblum; Alain Algazi; Simona Osella-Abate; Pietro Quaglino; Adil Daud; Susanna Ortiz-Urda
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

7.  Predicting disease progression after regional therapy for in-transit melanoma.

Authors:  Michael E Lidsky; Ryan S Turley; Georgia M Beasley; Ketan Sharma; Douglas S Tyler
Journal:  JAMA Surg       Date:  2013-06       Impact factor: 14.766

Review 8.  The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.

Authors:  Emmanuel Gabriel; Joseph Skitzki
Journal:  Cancers (Basel)       Date:  2015-07-01       Impact factor: 6.639

9.  Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma.

Authors:  Matthew Foote; Tavis Read; Janine Thomas; Michael Wagels; Bryan Burmeister; B Mark Smithers
Journal:  J Surg Oncol       Date:  2017-02-23       Impact factor: 3.454

10.  Treatment of in-transit melanoma with intralesional bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: a report of 3 cases.

Authors:  Nour Kibbi; Stephan Ariyan; Mark Faries; Jennifer N Choi
Journal:  J Immunother       Date:  2015 Nov-Dec       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.